uniQure to Participate in Multiple Conferences in February
01 February 2018 - 11:00PM
YASTEST
LEXINGTON, Mass. and AMSTERDAM,
the Netherlands, Feb. 01, 2018 (GLOBE NEWSWIRE) -- uniQure N.V.
(NASDAQ:QURE), a leader in human gene therapy, today announced that
members of company management or principal investigators will
participate in upcoming business, medical and investor conferences
during February.
- Bentley University
Innovator's Business Series, February 6, 2018 at Bentley University
in Waltham, Massachusetts.
o Matthew Kapusta, chief
executive officer of uniQure, will be the keynote speaker for a
presentation entitled, "Delivering on the Promise of Gene Therapy"
on Tuesday, February 6, 2018 at 5:00 p.m. EST.
- SunTrust 4th Annual
Orphan Drug Day, February 13, 2018 at the JW Marriott Essex House
in New York City
o Company management will be
hosting meetings with institutional investors throughout the
day.
- Leerink Partners
7th Annual
Global Healthcare Conference, February 14 - 15, 2018 at the Lotte
New York Palace Hotel in New York City
o Mr. Kapusta will be
participating in a Fireside Chat on Wednesday February 14, at 9:00
a.m. EST. The live webcast can be accessed by the link displayed in
the Investor section of the uniQure website. The webcast
replay will be available for at least 72 hours following the live
event.
- 13th Annual
Huntington's Disease Therapeutics Conference, February 26 - March
1, 2018 at the Parker Hotel in Palm Springs,
California
o Investigators at the Centre for Molecular Medicine and
Therapeutics & BC Children's Hospital Research Institute,
University of British Columbia, Vancouver, Canada, will present
novel, preclinical data on uniQure's proprietary investigational
gene therapy, AMT-130, in humanized mice models of Huntington's
disease. The presentation is expected to include data demonstrating
non-selective silencing of mutant HTT and improvements in select
behavioral and neuropathological Huntington's disease
phenotypes.
About
uniQure
uniQure is delivering on the promise of gene therapy - single
treatments with potentially curative results. We are leveraging our
modular and validated technology platform to rapidly advance a
pipeline of proprietary and partnered gene therapies to treat
patients with hemophilia, Huntington's disease and cardiovascular
diseases.
uniQure
Contacts
For Investors: |
|
Maria E. Cantor |
Direct:
339-970-7536 |
Mobile:
617-680-9452 |
m.cantor@uniQure.com |
|
Eva M. Mulder |
Direct:
+31 20 240 6103 |
Mobile:
+31 6 52 33 15 79 |
e.mulder@uniQure.com |
|
For Media: |
|
Tom Malone |
Direct: 339-970-7558 |
Mobile: 339-223-8541 |
t.malone@uniQure.com |
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: uniQure N.V. via Globenewswire
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Apr 2024 to May 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From May 2023 to May 2024